AHP BENEFIX RECOMBINANT FACTOR IX PRICED AT 8 [cents]/UNIT PREMIUM TO PLASMA-DERIVED PRODUCT; GENETICS INSTITUTE SHIPS FEB. 12; LABEL SPECIFIES DOSE ADJUSTMENT
Genetics Institute is selling BeneFix recombinant human factor IX at an average wholesale price of $1.18 per unit, an eight cent per unit premium to the plasma-derived factor IX products AlphaNine (Alpha Therapeutic) and Mononine (Centeon). BeneFix is available in single-dose vials of 250, 500 or 1,000 international units.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth